Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Neurology, Clinical care, Point of care testing

Brain Injury? There’s a Blood Test for That

What stat tests would you run on a patient with a traumatic brain injury? A CT scan? An MRI? Your thoughts may not immediately turn to blood testing, but new work by the University of Pennsylvania and the University of Michigan suggests that blood taken just after a brain injury can give us information about the patient’s prognosis (1).

The research focuses on two proteins, glial fibrillary acidic protein (GFAP), which is found in glial cells, and ubiquitin C-terminal hydrolase L1 (UCH-L1), which is found in neurons. Blood tests using this pair were approved by the US Food and Drug Administration in 2018 for use in determining whether a patient should have a CT scan after brain injury (2).

Now, researchers are interested in whether the GFAP–UCH-L1 pair can tell us how a patient’s brain function will fare after a traumatic injury. The study looked at available day-of-injury blood data from 1,696 patients and compared them with the same patients’ six-month assessments. The researchers ultimately found that GFAP and UCH-L1 plasma concentrations were strongly correlated with death (1). In fact, death prediction performed at a probability rate of 87 percent for GFAP and 89 percent for UCH-L1. For cases in which patients were left significantly disabled, both biomarkers achieved an 86 percent accuracy.

Where the tests fell short, however, was in predicting recovery, with accuracy reported at 62 percent for incomplete recovery and 61 percent for complete recovery. Seeing this, the researchers investigated whether testing both proteins at the same time and combining that information with other factors, such as age, increased accuracy.

Using this method, prediction accuracy in patients with moderate to severe TBI rose to 94 percent and 89 percent, respectively. The increase was smaller in patients with milder injuries, but accuracy in those cases nonetheless increased to 69 percent. These results corroborate previous findings and, though the tests were less effective at predicting factors such as incomplete recovery by six months, they demonstrate great potential for future use in predicting brain function, mortality, and more.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. FK Korley et al., “Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study,” Lancet Neurol, 21, 803 (2022).
  2. US Food and Drug Administration, “FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults” (2018). Available at: https://bit.ly/3P3WsLo.
About the Author
George Francis Lee

Associate Editor, The Pathologist

Like most people, I didn’t know exactly what I wanted to do after university. But one thing was certain – writing would play a central role. Not one to walk the path most traveled, I decided to spend my next few years freelancing to hone my skills as a writer and further cement my love for language. Reaching people through writing is important to me and I look forward to connecting with thousands of people through Texere’s passionate audience.

Related Application Notes
Biomarker Optimization on LabSat® Research

| Contributed by Lunaphore Technologies

Fast and automated TSA-based multiplexed immunofluorescence on LabSat® Research

| Contributed by Lunaphore Technologies

Specific Detection of RNA Expression and Distribution in Brain Using RNAscope® Technology

| Contributed by ACD

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register